文献速递血栓与止血

Marstacimab在无抑制物血友病A/B患者中的预防治疗:3期BASIS试验结果

Marstacimab prophylaxis in hemophilia A/B without inhibitors: results from the phase 3 BASIS trial.
PubMed 文献 · Blood · 2025-01-01

BASIS是一项开放标签3期试验,纳入12至74岁无抑制物的重型血友病A(FVIII<1%)或中重型至重型血友病B(FIX≤2%)男性患者,先在6个月观察期接受按需或常规预防治疗,后接受每周一次皮下150 mg marstacimab治疗12个月。按需组平均年化出血率从39.86降至3.20,常规预防组从7.90降至5.09,无死亡或血栓栓塞事件。

要点

  • 按需治疗组年化出血率从观察期39.86降至治疗期3.20,marstacimab优效(P<.0001)。
  • 常规预防组年化出血率从观察期7.90降至治疗期5.09,marstacimab非劣效且优效(P=.0349)。
  • 每周皮下150 mg marstacimab安全耐受,无死亡或血栓栓塞事件。

核心结论

  • 每周皮下注射marstacimab可较观察期按需或常规预防治疗降低无抑制物重型血友病A或中重型至重型血友病B患者的年化出血率,且安全耐受,无意外副作用。

研究设计与样本

  • BASIS为开放标签3期试验,纳入12至74岁无抑制物的重型血友病A(FVIII<1%)或中重型至重型血友病B(FIX≤2%)男性患者。
  • 观察期6个月接受按需或常规预防治疗,之后12个月活性治疗期接受每周一次皮下150 mg marstacimab。
  • 观察期入组128例,其中116例在活性治疗期接受marstacimab;按需组33例,常规预防组83例。

主要发现

  • 按需组平均年化出血率从观察期39.86(95%CI 33.05-48.07)降至治疗期3.20(95%CI 2.10-4.88),估计年化出血率比值0.080(95%CI 0.057-0.113),P<.0001。
  • 常规预防组平均年化出血率从观察期7.90(95%CI 5.14-10.66)降至治疗期5.09(95%CI 3.40-6.78),估计年化出血率差值-2.81(95%CI -5.42至-0.20),P=.0349。
  • 无死亡或血栓栓塞事件。

关键数值与推荐

  • 主要终点为治疗期治疗性出血的年化出血率与观察期按需或常规预防治疗比较,以及安全性。
  • 按需组marstacimab优效性检验P<.0001。
  • 常规预防组marstacimab非劣效性和优效性检验P=.0349。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Marstacimab targets the tissue factor pathway inhibitor to rebalance hemostasis. Previous phase 1 and 2 trials established marstacimab safety and efficacy in adults with severe hemophilia A (HA) or B (HB). BASIS is an open-label, marstacimab phase 3 trial in males aged 12 to 74 years with severe HA (factor VIII <1%) or moderately severe to severe HB (factor IX ≤2%). Participants without inhibitors received on-demand (OD) or routine prophylaxis (RP) therapy during a 6-month observational phase (OP) before receiving once-weekly subcutaneous 150 mg marstacimab during a 12-month active treatment phase (ATP). Primary end points were annualized bleeding rate (ABR) for treated bleeds vs previous OD or RP during the OP, and safety. Of 128 participants enrolled in the OP, 116 received marstacimab in the ATP. In the OD group (n = 33), mean ABR decreased from 39.86 (95% confidence interval [CI], 33.05-48.07) in the OP to 3.20 (95% CI, 2.10-4.88) in the ATP, demonstrating superiority of marstacimab (estimated ABR ratio, 0.080 [95% CI, 0.057-0.113]; P < .0001). In the RP group (n = 83), mean ABR decreased from 7.90 (95% CI, 5.14-10.66) in the OP to 5.09 (95% CI, 3.40-6.78) in the ATP, demonstrating noninferiority and superiority of marstacimab (estimated ABR difference, -2.81 [95% CI, -5.42 to -0.20]; P = .0349). There were no deaths or thromboembolic events. Weekly subcutaneous marstacimab reduced ABR vs OD or RP therapy in the OP in individuals with severe HA or moderately severe to severe HB without inhibitors. Marstacimab was safe and well tolerated with no unanticipated side effects. This trial was registered at www.clinicaltrials.gov as #NCT03938792.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Matino D, Palladino A, Taylor CT, et al. Marstacimab prophylaxis in hemophilia A/B without inhibitors: results from the phase 3 BASIS trial. Blood. 2025. PMID: 40608864. doi:10.1182/blood.2024027468

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。